News & insights
obesity
Articles from Apotek Analytics.
-

GLP-1 Drugs may risk investments in other essential treatments
Diabetes care in poorer settings drew attention from two directions.
-

Lilly’s retatrutide beats Ozempic. Artiva drops its autoimmune cell therapy after two trial deaths
Eli Lilly’s ‘triple-G’ drug retatrutide beat Novo Nordisk’s Ozempic on blood sugar and weight loss in a head-to-head phase 3 trial in type 2 diabetes, though with more side effects and treatment discontinuations.
-

Pfizer, Roche and AstraZeneca lead a week of drug discovery deals
Pfizer, Roche and AstraZeneca each struck discovery deals reported at $500m or more, as regulators in the UK, US and Europe signalled changes in how they weigh evidence.
-

NHS prescribing bill set to run about £460m above inflation in 2026, driven by GLP-1s
England’s NHS prescribing bill is on course to finish 2026 well ahead of inflation.
-

FDA approves AbbVie’s first-in-class Parkinson’s pill as pharma deal-making accelerates
The FDA approved AbbVie’s tavapadon, branded Juvmo, for adults with Parkinson’s disease, as deal-making dominated the rest of the week.